Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Enhanced in vitro virus expression using 3-dimensional cell culture spheroids for infection.

Rosellini A, Freer G, Quaranta P, Dovere V, Menichini M, Maggi F, Mazzetti P, Pistello M.

J Virol Methods. 2019 Mar;265:99-104. doi: 10.1016/j.jviromet.2018.12.017. Epub 2018 Dec 21.

PMID:
30582939
2.

Mouse mammary tumour virus-like env nucleotide and p14 signal peptide are present in feline mammary carcinomas, but not in neoplastic or dysplastic canine mammary lesions.

Civita P, Menicagli M, Scopelliti C, Lessi F, Millanta F, Borsacchi S, Parisi F, Freer G, Pistello M, Mazzanti CM, Poli A.

PLoS One. 2018 Jul 24;13(7):e0200839. doi: 10.1371/journal.pone.0200839. eCollection 2018.

3.

Does lung microbiome play a causal or casual role in asthma?

Di Cicco M, Pistello M, Jacinto T, Ragazzo V, Piras M, Freer G, Pifferi M, Peroni D.

Pediatr Pulmonol. 2018 Oct;53(10):1340-1345. doi: 10.1002/ppul.24086. Epub 2018 Jun 26.

PMID:
29943915
4.

The Virome and Its Major Component, Anellovirus, a Convoluted System Molding Human Immune Defenses and Possibly Affecting the Development of Asthma and Respiratory Diseases in Childhood.

Freer G, Maggi F, Pifferi M, Di Cicco ME, Peroni DG, Pistello M.

Front Microbiol. 2018 Apr 10;9:686. doi: 10.3389/fmicb.2018.00686. eCollection 2018. Review.

5.
6.

Virome and Inflammasomes, a Finely Tuned Balance with Important Consequences for the Host Health.

Freer G, Maggi F, Pistello M.

Curr Med Chem. 2019;26(6):1027-1044. doi: 10.2174/0929867324666171005112921. Review.

PMID:
28982318
7.

Evaluation of T Cell Immunity against Human Cytomegalovirus: Impact on Patient Management and Risk Assessment of Vertical Transmission.

Freer G, Quaranta P, Pistello M.

J Immunol Res. 2016;2016:9384813. doi: 10.1155/2016/9384813. Epub 2016 Dec 1. Review.

8.

Tweaking Mesenchymal Stem/Progenitor Cell Immunomodulatory Properties with Viral Vectors Delivering Cytokines.

Quaranta P, Focosi D, Freer G, Pistello M.

Stem Cells Dev. 2016 Sep 15;25(18):1321-41. doi: 10.1089/scd.2016.0145. Epub 2016 Sep 1. Review.

PMID:
27476883
9.

Human Wharton's jelly-derived mesenchymal stromal cells engineered to secrete Epstein-Barr virus interleukin-10 show enhanced immunosuppressive properties.

Quaranta P, Focosi D, Di Iesu M, Cursi C, Zucca A, Curcio M, Lapi S, Boldrini L, Stampacchia G, Paolicchi A, Scatena F, Freer G, Pistello M.

Cytotherapy. 2016 Feb;18(2):205-18. doi: 10.1016/j.jcyt.2015.11.011.

PMID:
26794713
10.

Intracellular staining and detection of cytokines by fluorescence-activated flow cytometry.

Freer G.

Methods Mol Biol. 2014;1172:221-34. doi: 10.1007/978-1-4939-0928-5_20.

PMID:
24908309
11.

Intracellular cytokine detection by fluorescence-activated flow cytometry: basic principles and recent advances.

Freer G, Rindi L.

Methods. 2013 May 15;61(1):30-8. doi: 10.1016/j.ymeth.2013.03.035. Epub 2013 Apr 11. Review.

PMID:
23583887
12.

Evaluation of underreporting tuberculosis in Central Italy by means of record linkage.

Melosini L, Vetrano U, Dente FL, Cristofano M, Giraldi M, Gabbrielli L, Novelli F, Aquilini F, Rindi L, Menichetti F, Freer G, Paggiaro PL.

BMC Public Health. 2012 Jun 21;12:472. doi: 10.1186/1471-2458-12-472.

13.

A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.

Chiuppesi F, Vannucci L, De Luca A, Lai M, Matteoli B, Freer G, Manservigi R, Ceccherini-Nelli L, Maggi F, Bendinelli M, Pistello M.

J Virol. 2012 Jun;86(12):6563-74. doi: 10.1128/JVI.00302-12. Epub 2012 Apr 4.

14.

Intracellular detection of interleukin 17 and other cytokines in human bronchoalveolar lavage fluid: a first assessment.

De Luca A, Rindi L, Celi A, Melosini L, Paggiaro P, Nelli LC, Garzelli C, Freer G.

Immunol Lett. 2012 Jan 30;141(2):204-9. doi: 10.1016/j.imlet.2011.10.005. Epub 2011 Oct 14.

PMID:
22020264
15.

Identification of a human immunodominant T-cell epitope of mycobacterium tuberculosis antigen PPE44.

Cuccu B, Freer G, Genovesi A, Garzelli C, Rindi L.

BMC Microbiol. 2011 Jul 25;11:167. doi: 10.1186/1471-2180-11-167.

16.

Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report.

Del Fabbro E, Hui D, Nooruddin ZI, Dalal S, Dev R, Freer G, Roberts L, Palmer JL, Bruera E.

J Pain Symptom Manage. 2010 Jun;39(6):1016-24. doi: 10.1016/j.jpainsymman.2009.09.021. Epub 2010 May 10.

PMID:
20457506
17.

Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Pistello M, Bonci F, Zabogli E, Conti F, Freer G, Maggi F, Stevenson M, Bendinelli M.

J Virol. 2010 Apr;84(8):3845-56. doi: 10.1128/JVI.02638-09. Epub 2010 Feb 3.

18.

Novel approaches to vaccination against the feline immunodeficiency virus.

Pistello M, Conti F, Vannucci L, Freer G.

Vet Immunol Immunopathol. 2010 Mar 15;134(1-2):48-53. doi: 10.1016/j.vetimm.2009.10.008. Epub 2009 Oct 14. Review.

PMID:
19896725
19.

Influence of dendritic cells on viral pathogenicity.

Freer G, Matteucci D.

PLoS Pathog. 2009 Jul;5(7):e1000384. doi: 10.1371/journal.ppat.1000384. Epub 2009 Jul 31. Review.

20.

A novel method for producing target cells and assessing cytotoxic T lymphocyte activity in outbred hosts.

Bonci F, Zabogli E, Conti F, Merico A, Freer G, Bendinelli M, Pistello M.

BMC Biotechnol. 2009 Mar 11;9:18. doi: 10.1186/1472-6750-9-18.

21.

In vitro antiviral activity of distamycin A against clinical isolates of herpes simplex virus 1 and 2 from transplanted patients.

Matteoli B, Bernardini S, Iuliano R, Parenti S, Freer G, Broccolo F, Baggiani A, Subissi A, Arcamone F, Ceccherini-Nelli L.

Intervirology. 2008;51(3):166-72. doi: 10.1159/000148199. Epub 2008 Jul 29.

PMID:
18663321
22.

Randomized study of phentolamine mesylate for reversal of local anesthesia.

Laviola M, McGavin SK, Freer GA, Plancich G, Woodbury SC, Marinkovich S, Morrison R, Reader A, Rutherford RB, Yagiela JA.

J Dent Res. 2008 Jul;87(7):635-9.

PMID:
18573982
23.

Immunotherapy with internally inactivated virus loaded dendritic cells boosts cellular immunity but does not affect feline immunodeficiency virus infection course.

Freer G, Matteucci D, Mazzetti P, Tarabella F, Ricci E, Bozzacco L, Merico A, Pistello M, Ceccherini-Nelli L, Bendinelli M.

Retrovirology. 2008 Apr 17;5:33. doi: 10.1186/1742-4690-5-33.

24.

A new fluorimetric assay to measure cytotoxic T-lymphocyte activity against feline immunodeficiency virus envelope glycoprotein.

Bonci F, Zabogli E, Freer G, Merico A, Bendinelli M, Pistello M.

Vet Immunol Immunopathol. 2008 May 15;123(1-2):150-3. doi: 10.1016/j.vetimm.2008.01.021. Epub 2008 Jan 19. Review. No abstract available.

PMID:
18304654
25.

Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus.

Freer G, Matteucci D, Mazzetti P, Tarabella F, Catalucci V, Ricci E, Merico A, Bozzacco L, Pistello M, Bendinelli M.

Clin Vaccine Immunol. 2008 Mar;15(3):452-9. doi: 10.1128/CVI.00421-07. Epub 2008 Jan 23.

26.

Streamlined design of a self-inactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes.

Pistello M, Vannucci L, Ravani A, Bonci F, Chiuppesi F, del Santo B, Freer G, Bendinelli M.

Genet Vaccines Ther. 2007 Sep 19;5:8.

27.

Effects of feline immunodeficiency virus on feline monocyte-derived dendritic cells infected by spinoculation.

Freer G, Matteucci D, Mazzetti P, Tarabella F, Catalucci V, Bendinelli M.

J Gen Virol. 2007 Sep;88(Pt 9):2574-82.

PMID:
17698669
28.

Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus.

Giannecchini S, Pistello M, Isola P, Matteucci D, Mazzetti P, Freer G, Bendinelli M.

J Virol. 2007 Oct;81(19):10474-85. Epub 2007 Jul 18.

29.

Antibodies generated in cats by a lipopeptide reproducing the membrane-proximal external region of the feline immunodeficiency virus transmembrane enhance virus infectivity.

Giannecchini S, D'Ursi AM, Esposito C, Scrima M, Zabogli E, Freer G, Rovero P, Bendinelli M.

Clin Vaccine Immunol. 2007 Aug;14(8):944-51. Epub 2007 Jun 27.

30.

AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Pistello M, Bonci F, Flynn JN, Mazzetti P, Isola P, Zabogli E, Camerini V, Matteucci D, Freer G, Pelosi P, Bendinelli M.

J Virol. 2006 Sep;80(18):8856-68.

31.

Generation of feline dendritic cells derived from peripheral blood monocytes for in vivo use.

Freer G, Matteucci D, Mazzetti P, Bozzacco L, Bendinelli M.

Clin Diagn Lab Immunol. 2005 Oct;12(10):1202-8.

32.

Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein.

Freer G, Giannecchini S, Tissot A, Bachmann MF, Rovero P, Serres PF, Bendinelli M.

Virology. 2004 May 1;322(2):360-9.

33.

Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection.

Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, Abrignani S, Uematsu Y.

Virology. 2002 Dec 20;304(2):187-96.

34.

Involvement of the fadD33 gene in the growth of Mycobacterium tuberculosis in the liver of BALB/c mice.

Rindi L, Fattorini L, Bonanni D, Iona E, Freer G, Tan D, Dehò G, Orefici G, Garzelli C.

Microbiology. 2002 Dec;148(Pt 12):3873-80.

PMID:
12480891
35.

Purification, biochemical characterization and immunogenicity of SA5K, a secretion antigen of Mycobacterium tuberculosis.

Batoni G, Bottai D, Esin S, Florio W, Pardini M, Maisetta G, Freer G, Senesi S, Campa M.

Scand J Immunol. 2002 Jul;56(1):43-51.

36.

Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization.

Pistello M, Moscardini M, Mazzetti P, Bonci F, Zaccaro L, Isola P, Freer G, Specter S, Matteucci D, Bendinelli M.

Virology. 2002 Jun 20;298(1):84-95.

37.

TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathology.

Pistello M, Morrica A, Maggi F, Vatteroni ML, Freer G, Fornai C, Casula F, Marchi S, Ciccorossi P, Rovero P, Bendinelli M.

J Med Virol. 2001 Feb;63(2):189-95.

PMID:
11170056
38.

Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans.

Bendinelli M, Pistello M, Maggi F, Fornai C, Freer G, Vatteroni ML.

Clin Microbiol Rev. 2001 Jan;14(1):98-113. Review.

39.

Qualitative and quantitative requirements for CD4+ T cell-mediated antiviral protection.

Maloy KJ, Burkhart C, Freer G, Rülicke T, Pircher H, Kono DH, Theofilopoulos AN, Ludewig B, Hoffmann-Rohrer U, Zinkernagel RM, Hengartner H.

J Immunol. 1999 Mar 1;162(5):2867-74.

40.

Analysis of the Mycobacterium bovis hsp60 promoter activity in recombinant Mycobacterium avium.

Batoni G, Maisetta G, Florio W, Freer G, Campa M, Senesi S.

FEMS Microbiol Lett. 1998 Dec 1;169(1):117-24.

41.

Identification and molecular cloning of a novel secretion antigen from Mycobacterium tuberculosis and Mycobacterium bovis BCG.

Freer G, Florio W, Dalla Casa B, Bottai D, Batoni G, Maisetta G, Senesi S, Campa M.

Res Microbiol. 1998 Apr;149(4):265-75.

PMID:
9766228
42.

Characterization of antigens recognized by new monoclonal antibodies raised against culture filtrate proteins of Mycobacterium bovis bacillus Calmette-Guérin.

Freer G, Florio W, Dalla Casa B, Castagna B, Maisetta G, Batoni G, Corsini V, Senesi S, Campa M.

FEMS Immunol Med Microbiol. 1998 Feb;20(2):129-38.

43.

Comparative analysis of subcellular distribution of protein antigens in Mycobacterium bovis bacillus Calmette-Guérin.

Florio W, Freer G, Daila Casa B, Batoni G, Maisetta G, Senesi S, Campa M.

Can J Microbiol. 1997 Aug;43(8):744-50.

PMID:
9304785
44.

The role of antibody concentration and avidity in antiviral protection.

Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, Roost H, Aguet M, Hengartner H, Zinkernagel RM.

Science. 1997 Jun 27;276(5321):2024-7.

45.

Correlation of tolerogenicity of a viral antigen with its immunogenicity.

Bachmann MF, Fehr T, Freer G, Hengartner H, Zinkernagel RM.

J Immunol. 1997 Jun 1;158(11):5106-11. Erratum in: J Immunol 1999 Jul 15;163(2):1091.

PMID:
9164925
46.

Cloning of an unidentified T-cell receptor alpha chain gene from a vesicular stomatitis virus-specific helper T-cell clone.

Ghelardi E, Burkhart C, Senesi S, Hengartner H, Freer G.

Immunol Lett. 1996 Oct;53(1):31-9.

PMID:
8946215
47.

Pleiotropic defects of IL-6-deficient mice including early hematopoiesis, T and B cell function, and acute phase responses.

Kopf M, Ramsay A, Brombacher F, Baumann H, Freer G, Galanos C, Gutierrez-Ramos JC, Köhler G.

Ann N Y Acad Sci. 1995 Jul 21;762:308-18. Review. No abstract available.

PMID:
7545368
48.

Role of T helper cell precursor frequency on vesicular stomatitis virus neutralizing antibody responses in a T cell receptor beta chain transgenic mouse.

Freer G, Burkhart C, Rülicke T, Ghelardi E, Rohrer UH, Pircher H, Zinkernagel RM, Hengartner H.

Eur J Immunol. 1995 May;25(5):1410-6.

PMID:
7539759
49.

Induction of protective cytotoxic T cells with viral proteins.

Bachmann MF, Kündig TM, Freer G, Li Y, Kang CY, Bishop DH, Hengartner H, Zinkernagel RM.

Eur J Immunol. 1994 Sep;24(9):2228-36.

PMID:
8088338
50.

Vesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen.

Freer G, Burkhart C, Ciernik I, Bachmann MF, Hengartner H, Zinkernagel RM.

J Virol. 1994 Jun;68(6):3650-5.

Supplemental Content

Support Center